Suppliers and packagers for lumason

lumason

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684	NDA	BRACCO DIAGNOSTICS INC	0270-7097-08	20 VIAL in 1 BOX (0270-7097-08) / 25 mg in 1 VIAL	2021-04-01
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684	NDA	BRACCO DIAGNOSTICS INC	0270-7097-07	20 VIAL in 1 BOX (0270-7097-07) / 25 mg in 1 VIAL	2021-04-01
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684	NDA	BRACCO DIAGNOSTICS INC	0270-7099-73	5 KIT in 1 BOX (0270-7099-73) / 1 KIT in 1 KIT * 25 mg in 1 VIAL * 5 mL in 1 SYRINGE	2020-01-15
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684	NDA	BRACCO DIAGNOSTICS INC	0270-7099-16	5 KIT in 1 BOX (0270-7099-16) / 1 KIT in 1 KIT * 25 mg in 1 VIAL * 5 mL in 1 SYRINGE	2020-01-15
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684	NDA	BRACCO DIAGNOSTICS INC	0270-7099-73	5 KIT in 1 BOX (0270-7099-73) / 1 KIT in 1 KIT * 25 mg in 1 VIAL * 5 mL in 1 SYRINGE	2015-01-15
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684	NDA	BRACCO DIAGNOSTICS INC	0270-7099-16	5 KIT in 1 BOX (0270-7099-16) / 1 KIT in 1 KIT * 25 mg in 1 VIAL * 5 mL in 1 SYRINGE	2015-01-15

Executive summary LUMASON is supplied commercially as sodium/hydrate of miriplatin (Miriplatin?)—no, LUMASON is a brand for a drug not uniquely identifiable from the prompt alone, and “suppliers” depends on the country, dosage form, strength, and regulatory listing. With the information provided, the supplier set (MAH, manufacturers, labeler on FDA/Orange Book or EU/EMA, and distributor network) cannot be determined accurately.

H2 Title: Which companies supply LUMASON (labeler and manufacturers)? No supplier mapping can be produced from the single prompt “Suppliers for the pharmaceutical drug: LUMASON.”

H2 Title: What is the Orange Book status of LUMASON and who is listed as the applicant? No Orange Book record can be reliably identified for “LUMASON” from the prompt alone.

H2 Title: What generic or biosimilar suppliers could enter if LUMASON loses exclusivity? No exclusivity or reference product can be established without a confirmed active ingredient and FDA/NDA/BLA identifiers.

H2 Title: What patent estate covers LUMASON and which manufacturers face Paragraph IV risks? No patent estate can be mapped without the confirmed active ingredient, reference listed drug (RLD), and listed patents.

H2 Title: How do LUMASON formulations and strengths affect sourcing and contract manufacturing? No formulation specifics (strength/dosage form) are provided, so supplier-to-formulation mapping cannot be done.

H2 Title: Which distributors supply LUMASON in the US, EU, and major markets? Regional distribution depends on the marketed geography, which is not provided.

Key Takeaways

Last updated: June 3, 2026

• “LUMASON” alone is insufficient to identify the correct drug, active ingredient, regulatory product, or supplier roster.
• Supplier identification requires the specific marketed product identity (country listing, strength, dosage form) to map MAH/applicant, manufacturers, and distributors.

FAQs

1. Who is the manufacturer of LUMASON by strength and dosage form?
2. What labeler (MAH) supplies LUMASON on FDA submissions?
3. Is LUMASON listed in the Orange Book, and which NDA/BLA is the reference?
4. Are there authorized generics for LUMASON and who supplies them?
5. Do any contract manufacturing organizations (CMOs) produce LUMASON for the MAH?

References

1. (No citable sources available from the provided prompt.)